The lyme disease vaccine-A public health perspective

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 3, 2011, Pages

  Shen, Angela K ^a   Mead, Paul S ^b   Beard, Charles B ^b  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARICIDE; INSECT REPELLENT; LYME DISEASE VACCINE;

ARTHRALGIA; ARTICLE; ASTHENIA; BORRELIA BURGDORFERI; CLOTHING; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; GEOGRAPHIC DISTRIBUTION; HEADACHE; HUMAN; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; LAND USE; LYME DISEASE; MOLECULAR GENETICS; MYALGIA; NONHUMAN; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RASH; ANIMAL; DISEASE TRANSMISSION; IMMUNOLOGY; MICROBIOLOGY; PARASITE VECTOR; PUBLIC HEALTH; REVIEW; RISK FACTOR; TICK; UNITED STATES;

ANIMALS; ARACHNID VECTORS; BORRELIA BURGDORFERI; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYME DISEASE; LYME DISEASE VACCINES; PUBLIC HEALTH; RISK FACTORS; TICKS; UNITED STATES;

EID: 79952562288     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq115     Document Type: Article

References (20)

1. Steere AC Lyme disease. N Engl J Med 2001; 345:115-125. (Pubitemid 32640193)
2. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113:1093-1101. (Pubitemid 38544091)
3. Centers for Disease Control and Prevention. Notice to readers: final 2009 reports ofnationally notifiable infectious diseases. MMWR Morb Mortal Wkly Rep 2010; 59:1025-1053.
4. Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease-United States, 1992-2006. MMWR Surveill Summ 2008; 57:1-9.
5. Ertel S, Altier H, Nealson R, Cartter M. Lyme disease\Connecticut, 2008. Conn Epidemiologist 2009; 29:14-16.
6. Waller L, Goodwin B, Wilson M, Ostfeld R, Marshell S, Hayes E. Spatiotemporal patterns in countylevel incidence and reporting of Lyme disease in the northeastern United States. Environ Ecol Stat 2007; 14:83-100. (Pubitemid 46291429)
7. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorfer i outersurface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339:209-215. (Pubitemid 28350162)
8. Centers for Disease Control and Prevention. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1-17, 21-25.
9. Lathrop SL, Ball R, Haber P, et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002; 20:1603-1608. (Pubitemid 34169801)
10. Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J Pediatr 1997; 131:529-535. (Pubitemid 28006923)
11. Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect 2007; 135:1-8. (Pubitemid 44811480)
12. Hitt E. Poor sales trigger vaccine withdrawal. Nat Med 2002; 8:311-312. (Pubitemid 34407011)
13. Plotkin SA.Why certainvaccines have been delayed or not developedat all. Health Aff (Millwood) 2005; 24:631-634.
14. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003; 348:2424-2430. (Pubitemid 36682822)
15. Poland GA. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2001; 76:713-724. (Pubitemid 32595422)
16. Gould LH, Nelson RS, Griffith KS, et al. Knowledge, attitudes, and behaviors regarding Lyme disease prevention among Con-necticut residents, 1999-2004. Vector Borne Zoonotic Dis 2008; 8:769-776.
17. Connally NP, Durante AJ, Yousey-Hindes KM, Meek JI, Nelson RS, Heimer R. Peridomestic Lyme disease prevention: results of a population-based case-control study. Am J Prev Med 2009; 37:201-206.
18. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assess-ment, treatment, prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the In-fectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-1134. (Pubitemid 44637131)
19. Poland GA, Jacobson RM. The prevention of Lyme disease with vac-cine. Vaccine 2001; 19:2303-2308.
20. Dixon B. Lyme disease-The public dimension. Microbe 2007; 2:114-115.